Schizophrenia Spectrum Disorders
16
5
6
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 16 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 6 completed trials
Clinical Trials (16)
A Case Series of Culturally-adapted CBTp for Black People in the UK
Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity
Using Illusions to Boost Social Cognition
Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders
Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders
Gamma Light and Sound Stimulation in Schizophrenia
ENGAGE: Virtual Reality-based Psychotherapy for Negative Symptoms in Schizophrenia
OXYMIND: Oxytocin-augmented Group Psychotherapy for Patients With Schizophrenia
MI-CBTech: A Mobile Intervention for Community Integration in Homeless-Experienced Veterans With SMI
Neurophysiologic Biomarkers for Cognitive Rehabilitation
Health Outcomes Via Positive Engagement in Schizophrenia
Safety and Efficacy of Virtual Reality Mindfulness in Patients With Psychosis
Game-based Telehealth Therapeutic Intervention in First Onset Psychosis
The Association of Affective Resonance With Empathy Modulated by Negative Symptomatology and Oxytocin
Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis
A Problem-solving Based Bibliotherapy Program for Family Caregivers in Schizophrenia